Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr., Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. 2001. Final version of the american joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648.
Behrmann I, Wallner S, Komyod W, Heinrich PC, Schuierer M, Buettner R, Bosserhoff AK. 2003. Characterization of methyl- thioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol 163:683–690.
Beswick S, Affleck P, Elliott F, Gerry E, Boon A, Bale L, Nolan C, Barrett JH, Bertram C, Marsden J, Bishop DT, Newton- Bishop JA. 2008. Environmental risk factors for relapse of melanoma. Eur J. Cancer 44:1717–1725.
Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A, Tucker MA. 2002. Geo- graphical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94:894–903.
Buffart TE, van Grieken NC, Tijssen M, Coffa J, Ylstra B, Grabsch HI, van de Velde CJ, Carvalho B, Meijer GA. 2009. High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch 455:213–223.
Cachia AR, Indsto JO, McLaren KM, Mann GJ, Arends MJ. 2000. CDKN2A mutation and deletion status in thin and thick primary melanoma. Clin Cancer Res 6:3511–3515.
Chen ZH, Zhang H, Savarese TM. 1996. Gene deletion chemose- lectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Cancer Res 56:1083–1090.
Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, Nsen- gimana J, Edward S, Sanders DS, Cook M, Powell B, Boon A, Elliott F, de Kort F, Knowles MA, Bishop DT, Newton-Bishop J. 2009. Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 15:6939–6946.
Edlundh-Rose E, Egyhazi S, Omholt K, Mansson-Brahme E, Platz A, Hansson J, Lundeberg J. 2006. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16:471–478.
Elder DE, Murphy GF. 2010. Melanocytic tumors of the skin. Washington, DC, American Registry of Pathology, in press.
Flores JF, Walker GJ, Glendening JM, Haluska FG, Castresana JS, Rubio MP, Pastorfide GC, Boyer LA, Kao WH, Bulyk ML, Barnhill RL, Hayward NK, Housman DE, Fountain JW. 1996. Loss of the p16INK4a and p15INK4b genes, as well as neigh- boring 9p21 markers, in sporadic melanoma. Cancer Res 56:5023–5032.
Freedberg DE, Mistry S, Russak J, Gai W, Kaplow M, Osman I, Turner F, Houghton A, Busam K, Bishop T, Bastian B, Bishop J-N, Polsky D. 2008. Genetic and epigenetic alteration of p14ARF is frequent in human melanoma metastases. J Natl Cancer Inst 100:784–795.
Fujimoto A, Morita R, Hatta N, Takehara K, Takata M. 1999. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma. Oncogene 18:2527–2532.
Funk JO, Schiller PI, Barrett MT, Wong DJ, Kind P, Sander CA. 1998. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan Pathol 25:291–296.
Garnett MJ, Marais R. 2004. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313–319.
Gimotty PA, Botbyl J, Soong SJ, Guerry D. 2005. A population- based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 23:8065–8075.
Goldstein AM, Tucker MA. 2001. Genetic epidemiology of cutaneous melanoma: A global perspective. Arch Dermatol 137:1493–1496.
Gonzalgo ML, Bender CM, You EH, Glendening JM, Flores JF, Walker GJ, Hayward NK, Jones PA, Fountain JW. 1997. Low frequency of p16/CDKN2A methylation in sporadic melanoma: Comparative approaches for methylation analysis of primary tumors. Cancer Res 57:5336–5347.
Grafstrom E, Egyhazi S, Ringborg U, Hansson J, Platz A. 2005. Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival. Clin Cancer Res 11:2991–2997.
Greene VR, Johnson MM, Grimm EA, Ellerhorst JA. 2009. Fre- quencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J Invest Dermatol 129:1483–1488.
Ha L, Merlino G, Sviderskaya EV. 2008. Melanomagenesis: Over- coming the barrier of melanocyte senescence. Cell Cycle 7:1944–1948.
Jarinova O, Stewart AF, Roberts R, Wells G, Lau P, Naing T, Buerki C, McLean BW, Cook RC, Parker JS, McPherson R. 2009. Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol 29:1671–1677.
Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH. 1994a. A cell cycle regulator potentially involved in gene- sis of many tumor types. Science 264:436–440.
Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright L. 1994b. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:23–26.
Koynova D, Jordanova E, Kukutsch N, van der Velden P, Toncheva D, Gruis N. 2007. Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma. J Cancer Res Clin Oncol 133:117–123.
Krimpenfort P, Ijpenberg A, Song JY, van der Valk M, Nawijn M, Zevenhoven J, Berns A. 2007. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature 448:943–946.
Kumar R, Angelini S, Hemminki K. 2003. Activating BRAF and N-Ras mutations in sporadic primary melanomas: An inverse association with allelic loss on chromosome 9. Oncogene 22:9217–9224.
Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Mohlke KL, Ibra- him JG, Thomas NE, Sharpless NE. 2009. INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS ONE 4:e5027.
Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuil- man T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. 2005. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720–724.
Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ, Schouten JP, Errami A. 2005. Methylation-specific MLPA (MS-MLPA): Simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 33:e128.
Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. 2003. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9:6483–6488.
Pasmant E, Laurendeau I, Heron D, Vidaud M, Vidaud D, Bieche I. 2007. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: Identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 67:3963–3969.
Pavey SJ, Cummings MC, Whiteman DC, Castellano M, Walsh MD, Gabrielli BG, Green A, Hayward NK. 2002. Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res 12:539–547.
Peters G. 2008. Tumor suppression for ARFicionados: The rela- tive contributions of p16INK4a and p14ARF in melanoma. J Natl Cancer Inst 100:757–759.
Platz A, Egyhazi S, Ringborg U, Hansson J. 2008. Human cutaneous melanoma: A review of NRAS and BRAF mutation fre- quencies in relation to histogenetic subclass and body site. Mol Oncol 1:395–405.
Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, Redman B, Thomas NE, Gruber SB. 2006. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16:267–273.
Rizos H, Darmanian AP, Indsto JO, Shannon JA, Kefford RF, Mann GJ. 1999. Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells. Melanoma Res 9:10–19.
Rodolfo M, Daniotti M, Vallacchi V. 2004. Genetic progression of metastatic melanoma. Cancer Lett 214:133–147.
Roussel MF. 1999. The INK4 family of cell cycle inhibitors in cancer. Oncogene 18:5311–5317.
Ruiz A, Puig S, Lynch M, Castel T, Estivill X. 1998. Retention of the CDKN2A locus and low frequency of point mutations in primary and metastatic cutaneous malignant melanoma. Int J Cancer 76:312–316.
Schlegel NC, Eichhoff OM, Hemmi S, Werner S, Dummer R, Hoek KS. 2009. Id2 suppression of p15 counters TGF-beta- mediated growth inhibition of melanoma cells. Pigment Cell Melanoma Res 22:445–453.
Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. 2002. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57.
Sharpless NE, DePinho RA. 1999. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 9:22–30.
Straume O, Smeds J, Kumar R, Hemminki K, Akslen LA. 2002. Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol 161:229–237.
Takata M. 2008. Detection of copy number changes at multiple loci in DNA prepared from formalin-fixed, paraffin-embedded tissue by multiplex ligation-dependent probe amplification. Methods Mol Biol 439:101–108.
Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T. 1997. Loss of expression of the p16 (INK4)/cdkn2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 74:255–259.
Tran TP, Titus-Ernstoff L, Perry AE, Ernstoff MS, Newsham IF. 2002. Alteration of chromosome 9p21 and/or p16 in benign and dysplastic nevi suggests a role in early melanoma progression (United States). Cancer Causes Control 13:675–682.
van Dijk MC, Rombout PD, Boots-Sprenger SH, Straatman H, Bernsen MR, Ruiter DJ, Jeuken JW. 2005. Multiplex ligation-dependent probe amplification for the detection of chromosomal gains and losses in formalin-fixed tissue. Diagn Mol Pathol 14:9–16.
von Eggeling F, Werner G, Theuer C, Riese U, Dahse R, Fiedler W, Schimmel B, Ernst G, Karte K, Claussen U, Wollina U. 1999. Analysis of the tumor suppressor gene p16(INK4A) in microdis- sected melanoma metastases by sequencing, and microsatellite and methylation screening. Arch Dermatol Res 291:474–477.
Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, Fountain JW. 1998. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 22:157–163.
Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1:20–26.
Wild PJ, Meyer S, Landthaler M, Hofstaedter F, Bosserhoff AK. 2007. A potential predictive marker for response to interferon in malignant melanoma. J Dtsch Dermatol Ges 5:456–459.
Zhang H, Rosdahl I. 2004. Deletion in p16INK4a and loss of p16 expression in human skin primary and metastatic melanoma cells. Int J Oncol 24:331–335.
Zhao Y, Zhang Y, Yang Z, Li A, Dong J. 2008. Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis. Biochem Biophys Res Commun 370:509–513.